drugset / Trial / NCT02063958
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
NaSingle-groupOpen-labelTreatment
Summary
Study is designed to determine the maximum tolerated dose (MTD) of SNX-5422 when given in combination with everolimus.
Timeline
- Start
- 2014-02
- Primary completion
- 2017-03-27
- Completion
- 2018-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SNX-5422 | Small molecule | 50 mg/m2 | — |
| Subject | SNX-5422 | Small molecule | 100 mg/m2 | — |